Cover Image
Market Research Report

Respiratory Tract Infections Drug Development Pipeline Review, 2018

Published by GlobalData Product code 676513
Published Content info 153 Pages
Delivery time: 1-2 business days
Price
Back to Top
Respiratory Tract Infections Drug Development Pipeline Review, 2018
Published: July 31, 2018 Content info: 153 Pages
Description

Summary:

Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in the body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest. There are 206 products in development for this indication.

Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever and chills and malaise. Treatment includes antitoxins and antibiotics. There are 31 products in development for this indication.

Pertussis is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Symptoms include runny nose, nasal congestion, sneezing, red, watery eyes and dry cough. Treatment includes antibiotics. There are 40 products in development for this indication.

Molecular targets acted on by products in development for respiratory tract infections include bacterial proteins and toxins. Companies operating in this pipeline space include Beijing Minhai Biotechnology, Sanofi and GlaxoSmithKline.

This report "Respiratory Tract Infections Drug Development Pipeline Review, 2018" provides an overview of the pipeline landscape for respiratory tract infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for tuberculosis, diphtheria and pertussis (whooping cough), and features dormant and discontinued products.

Scope:

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy:

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Table of Contents
Product Code: GBIHC042IDB

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Respiratory Tract Infections Report Coverage
  • 2.2. Tuberculosis - Overview
  • 2.3. Diphtheria - Overview
  • 2.4. Pertussis (Whooping Cough) - Overview

3. Therapeutics Development

  • 3.1. Tuberculosis
  • 3.2. Diphtheria
  • 3.3. Pertussis (Whooping Cough)

4. Therapeutics Assessment

  • 4.1. Tuberculosis
  • 4.2. Diphtheria
  • 4.3. Pertussis (Whooping Cough)

5. Companies Involved in Therapeutics Development

  • 5.1. Tuberculosis
  • 5.2. Diphtheria
  • 5.3. Pertussis (Whooping Cough)

6. Dormant Projects

  • 6.1. Tuberculosis
  • 6.2. Diphtheria
  • 6.3. Pertussis (Whooping Cough)

7. Discontinued Products

  • 7.1. Tuberculosis
  • 7.2. Diphtheria
  • 7.3. Pertussis (Whooping Cough)

8. Product Development Milestones

  • 8.1. Tuberculosis
  • 8.2. Diphtheria
  • 8.3. Pertussis (Whooping Cough)

9. Appendix

  • 9.1. Methodology
  • 9.2. Coverage
  • 9.3. Secondary Research
  • 9.4. Primary Research
  • 9.5. Expert Panel Validation
  • 9.6. Contact Us
  • 9.7. Disclaimer

List of Tables

  • Table 1: Number of Products under Development for Tuberculosis
  • Table 2: Number of Products under Development by Companies Tuberculosis
  • Table 3: Number of Products under Development by Universities/Institutes Tuberculosis
  • Table 4: Products under Development by Companies Tuberculosis
  • Table 5: Products under Development by Universities/Institutes Tuberculosis
  • Table 6: Number of Products under Development for Diphtheria
  • Table 7: Number of Products under Development by Companies Diphtheria
  • Table 8: Number of Products under Development by Universities/Institutes Diphtheria
  • Table 9: Products under Development by Companies Diphtheria
  • Table 10: Products under Development by Universities/Institutes Diphtheria
  • Table 11: Number of Products under Development for Pertussis (Whooping Cough)
  • Table 12: Number of Products under Development by Companies Pertussis (Whooping Cough)
  • Table 13: Number of Products under Development by Universities/Institutes Pertussis (Whooping Cough)
  • Table 14: Products under Development by Companies Pertussis (Whooping Cough)
  • Table 15: Products under Development by Universities/Institutes Pertussis (Whooping Cough)
  • Table 16: Number of Products by Stage and Target Tuberculosis
  • Table 17: Number of Products by Stage and Mechanism of Action Tuberculosis
  • Table 18: Number of Products by Stage and Route of Administration Tuberculosis
  • Table 19: Number of Products by Stage and Molecule Type Tuberculosis
  • Table 20: Number of Products by Stage and Target Diphtheria
  • Table 21: Number of Products by Stage and Route of Administration Diphtheria
  • Table 22: Number of Products by Stage and Molecule Type Diphtheria
  • Table 23: Number of Products by Stage and Target Pertussis (Whooping Cough)
  • Table 24: Number of Products by Stage and Mechanism of Action Pertussis (Whooping Cough)
  • Table 25: Number of Products by Stage and Route of Administration Pertussis (Whooping Cough)
  • Table 26: Number of Products by Stage and Molecule Type Pertussis (Whooping Cough)
  • Table 27: Tuberculosis - Pipeline by Abera Bioscience AB
  • Table 28: Tuberculosis - Pipeline by AGILeBiotics BV
  • Table 29: Tuberculosis - Pipeline by Akshaya Bio Inc
  • Table 30: Tuberculosis - Pipeline by Archivel Farma SL
  • Table 31: Tuberculosis - Pipeline by AstraZeneca Plc
  • Table 32: Tuberculosis - Pipeline by Aucta Pharmaceuticals LLC
  • Table 33: Tuberculosis - Pipeline by BioLingus AG
  • Table 34: Tuberculosis - Pipeline by Bioversys AG
  • Table 35: Tuberculosis - Pipeline by Celgene Corp
  • Table 36: Tuberculosis - Pipeline by Chongqing Zhifei Biological Products Co Ltd
  • Table 37: Tuberculosis - Pipeline by Consegna Pharma Inc
  • Table 38: Tuberculosis - Pipeline by Crestone Inc
  • Table 39: Tuberculosis - Pipeline by Daiichi Sankyo Co Ltd
  • Table 40: Tuberculosis - Pipeline by Demuris Ltd
  • Table 41: Tuberculosis - Pipeline by Eisai Co Ltd
  • Table 42: Tuberculosis - Pipeline by Eli Lilly and Co
  • Table 43: Tuberculosis - Pipeline by EpiVax Inc
  • Table 44: Tuberculosis - Pipeline by Evotec AG
  • Table 45: Tuberculosis - Pipeline by FIT Biotech Oy
  • Table 46: Tuberculosis - Pipeline by GangaGen Inc
  • Table 47: Tuberculosis - Pipeline by GC Pharma
  • Table 48: Tuberculosis - Pipeline by GlaxoSmithKline Plc
  • Table 49: Tuberculosis - Pipeline by Globeimmune Inc
  • Table 50: Tuberculosis - Pipeline by Hager Biosciences LLC
  • Table 51: Tuberculosis - Pipeline by Hsiri Therapeutics LLC
  • Table 52: Tuberculosis - Pipeline by Immodulon Therapeutics Ltd
  • Table 53: Tuberculosis - Pipeline by Immunitor Inc

List of Figures

  • Figure 1: Number of Products under Development for Tuberculosis
  • Figure 2: Number of Products under Development by Companies Tuberculosis
  • Figure 3: Number of Products under Development by Universities/Institutes Tuberculosis
  • Figure 4: Number of Products under Development for Diphtheria
  • Figure 5: Number of Products under Development by Companies Diphtheria
  • Figure 6: Number of Products under Development by Universities/Institutes Diphtheria
  • Figure 7: Number of Products under Development for Pertussis (Whooping Cough)
  • Figure 8: Number of Products under Development by Companies Pertussis (Whooping Cough)
  • Figure 9: Number of Products under Development by Universities/Institutes Pertussis (Whooping Cough)
  • Figure 10: Number of Products by Top 10 Targets Tuberculosis
  • Figure 11: Number of Products by Stage and Top 10 Targets Tuberculosis
  • Figure 12: Number of Products by Top 10 Mechanism of Actions Tuberculosis
  • Figure 13: Number of Products by Stage and Top 10 Mechanism of Actions Tuberculosis
  • Figure 14: Number of Products by Routes of Administration Tuberculosis
  • Figure 15: Number of Products by Stage and Routes of Administration Tuberculosis
  • Figure 16: Number of Products by Top 10 Molecule Types Tuberculosis
  • Figure 17: Number of Products by Stage and Top 10 Molecule Types Tuberculosis
  • Figure 18: Number of Products by Targets Diphtheria
  • Figure 19: Number of Products by Stage and Targets Diphtheria
  • Figure 20: Number of Products by Routes of Administration Diphtheria
  • Figure 21: Number of Products by Stage and Routes of Administration Diphtheria
  • Figure 22: Number of Products by Molecule Types Diphtheria
  • Figure 23: Number of Products by Stage and Molecule Types Diphtheria
  • Figure 24: Number of Products by Targets Pertussis (Whooping Cough)
  • Figure 25: Number of Products by Stage and Targets Pertussis (Whooping Cough)
  • Figure 26: Number of Products by Routes of Administration Pertussis (Whooping Cough)
  • Figure 27: Number of Products by Stage and Routes of Administration Pertussis (Whooping Cough)
  • Figure 28: Number of Products by Top 10 Molecule Types Pertussis (Whooping Cough)
  • Figure 29: Number of Products by Stage and Molecule Types Pertussis (Whooping Cough)
Back to Top